The comparison credits Novo with stronger profitability and a cheaper valuation, but Amgen grew revenue 9.9% in FY 2025 versus Novo's 6.4%.
Recap by typeshit. Post by Investseekers on X.
An investing platform's company history runs from Lilly's 1876 founding through Humulin and Prozac to its obesity drug boom. Background, not news.
Generic advice that a lack of hunger doesn't mean you've eaten enough, with a nudge toward smaller portions built around protein.
Dr. Mimi Tan points to a wider set of obesity treatments and notes Ozempic is the semaglutide brand meant for type 2 diabetes.
Brian Underwood shares that the Men's Health fall issue starring Drake Maye is on newsstands, with peptides among the topics inside.
The firm argues GLP-1 wins proved peptides work as a drug platform, covering oral macrocycles and AI-driven discovery.
IE Lifestyle reports on new research tying GLP-1 use to nail and hair problems, with two experts weighing in on the findings.
Loading…